Decreased LT-β expression and concurrent increased LT-α expression on B cells may indicate that in cancer patients the canonic LT-α1β2 ligand complex that reacts with LT-βR is substituted by the LT-α2β1 complex that does not react with this receptor. The gene discussed is LTB; the disease is cancer.